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Abstract: Activation of the nod-like receptor 3 (NLRP3) inflammasomes is crucial for immune defense,
but improper and excessive activation causes inflammatory diseases. We previously reported that
Cbl plays a pivotal role in suppressing NLRP3 inflammasome activation by inhibiting Pyk2-mediated
apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization. Here, we showed
that Cbl dampened NLRP3 inflammasome activation by inhibiting glycolysis, as demonstrated
with Cbl knockout cells and treatment with the Cbl inhibitor hydrocotarnine. We revealed that
the inhibition of Cbl promoted caspase-1 cleavage and interleukin (IL)-1β secretion through a
glycolysis-dependent mechanism. Inhibiting Cbl increased cellular glucose uptake, glycolytic
capacity, and mitochondrial oxidative phosphorylation capacity. Upon NLRP3 inflammasome
activation, inhibiting Cbl increased glycolysis-dependent activation of mitochondrial respiration and
increased the production of reactive oxygen species, which contributes to NLRP3 inflammasome
activation and IL-1β secretion. Mechanistically, inhibiting Cbl increased surface expression of
glucose transporter 1 (GLUT1) protein through post-transcriptional regulation, which increased
cellular glucose uptake and consequently raised glycolytic capacity, and in turn enhanced NLRP3
inflammasome activation. Together, our findings provide new insights into the role of Cbl in NLRP3
inflammasome regulation through GLUT1 downregulation. We also show that a novel Cbl inhibitor,
hydrocortanine, increased NLRP3 inflammasome activity via its effect on glycolysis.
Keywords: Cbl; NLRP3; inflammasome; glycolysis; GLUT1
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1. Introduction
Nod-like receptor 3 (NLRP3) inflammasome is a cytoplasmic multiprotein complex that is
crucial for innate immunity. It is composed of a cytosolic pattern recognition receptor, NLRP3,
along with the adaptor protein, apoptosis-associated speck-like protein containing a CARD (ASC),
and pro-caspase-1 [1]. Nod-like receptor 3 inflammasome assembly is initiated by NLRP3
oligomerization, which recruits ASC to activate caspase-1, and in turn mediates the secretion of
proinflammatory cytokines interleukin (IL)-1β and IL-18 [2]. Nod-like receptor 3 is a critical component
required for inflammasome activation in response to some pathogen-associated molecular patterns
(PAMPs) and damage-associated molecular patterns (DAMPs), such as nigericin, a pore-forming
toxin derived from Streptomyces hygroscopicus [3]. Mice deficient in NLRP3 are very susceptible
to microbial infection [4]. In addition, increasing evidence suggests that improper and excessive
activation is responsible for the pathogenesis of several inflammation-associated diseases, including
type 2 diabetes [5], septic shock [6], gout [7], atherosclerosis [8], rheumatoid arthritis [9], Alzheimer’s
disease [10], cryopyrin-associated periodic syndrome [11], and cancer [12].
Several lines of evidence support the notion that reactive oxygen species (ROS) contribute to
NLRP3 inflammasome activation [13–15]. Mitochondria are the major source of cellular ROS, which are
generated as by-products of oxidative metabolism. Depletion of mitochondrial DNA (mtDNA) with
chronic ethidium bromide treatment reduces mitochondrial reactive oxygen species (mtROS) production
and inhibits NLRP3 inflammasome activation in the J774A.1 macrophage cell line [14]. Blocking
the electron transport chain by using mitochondrial complex I inhibitor rotenone [16] or complex III
inhibitor antimycin A [17] induces mtROS production. This enhancement of mtROS production is
sufficient for activating NLRP3 inflammasomes, which suggests that mtROS is an activator of NLRP3
inflammasomes [15]. Nigericin induces mtROS production and NLRP3 inflammasome activation in
macrophages, whereas treatment with mito-TEMPO, a mitochondria-specific ROS scavenger, can block
NLRP3 inflammasome activation [18]. Furthermore, nigericin-induced mtROS production results
in the induction and release of oxidatively modified mtDNA into the cytosol, where it binds to and
activates NLRP3 inflammasomes [19]. Activation of the NLRP3 inflammasomes by oxidized mtDNA
was supported in a recent study by Zhong et al., which showed that increasing mtDNA due to new
synthesis enhanced NLRP3 inflammasome activation [20].
Emerging evidence also indicates that glycolysis is essential for NLRP3 inflammasome activation
in macrophages [21,22]. Glycolysis converts glucose into pyruvate, which is used to yield energy for
the cell during aerobic respiration through mitochondrial oxidative phosphorylation (OXPHOS) or
during anaerobic lactic acid fermentation. Hexokinase 1, the enzyme of first step in glycolysis, catalyzes
glucose to produce glucose-6-phosphate, and it was shown to be required for mtROS production
and NLRP3 inflammasome activation in response to adenosine triphosphate (ATP) stimulation [21].
Pyruvate kinase, the enzyme involved in the last step in glycolysis, catalyzes phosphoenolpyruvate to
generate pyruvate and it is required for ATP-induced NLRP3 inflammasome activation [22].
The proto-oncogene Cbl encodes a ubiquitin ligase belonging to the Cbl family, and mediates
protein ubiquitination [23]. This protein contains an N-terminal phosphotyrosine-binding domain
that allows it to interact with numerous tyrosine-phosphorylated substrates, targeting them for
proteasomal or lysosomal degradation. Thus, the Cbl proteins function as a negative regulator of many
signal transduction pathways. Our previous report revealed that Cbl is pivotal in suppressing NLRP3
inflammasome activation in response to stimulation by nigericin or ATP by inhibition of Pyk2-dependent
ASC oligomerization [24,25]. Phosphorylated Pyk2 (p-Pyk2) can directly phosphorylate ASC at
Tyr146 [24]—such phosphorylation is required for ASC oligomerization and the sequential formation
of the NLRP3 inflammasomes [25,26]. Through the ubiquitination-mediated proteasomal degradation
of p-Pyk2, Cbl reduces the level of p-Pyk2 and inhibits NLRP3 inflammasome activation. In addition,
Cbl plays a role in energy homeostasis in a Cbl-knockout (KO) mice [27]. Cbl-KO mice exhibit a
profound increase in whole-body energy expenditure, as determined by increased core temperature and
whole-body oxygen consumption. The Cbl-KO mice also display marked improvement in whole-body
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insulin action and glucose tolerance. Consistent with our previous studies, the size of the mitochondria
was found to be enlarged in Cbl-deficient cells [24,27]. All these observations suggest that Cbl is
involved in the regulation of energy homeostasis, although the underlying mechanism has not been
identified yet.
In this study, we discovered that Cbl dampens NLRP3 inflammasome activation through glycolysis
inhibition. Cbl acts through a post-transcriptional mechanism to reduce the amount of glucose
transporter 1 (GLUT1) protein available for cellular glucose uptake, which in turn affects the capacities
of glycolysis and mitochondrial oxidative phosphorylation (OXPHOS). The low level of glycolysis,
regulated by Cbl, further dampens NLRP3 inflammasome activation. Together, our findings provide
new insights into the role of the Cbl in suppressing NLRP3 inflammasome activation through
glycolysis inhibition.
2. Results
2.1. Cbl Inhibition Increased the Rate of Glycolysis and Oxidative Phosphorylation
We had previously observed that Cbl acts as a negative regulator of NLRP3 inflammasomes [24]
and it may be involved in the regulation of glucose tolerance [27]. Recent reports have indicated
that glycolysis contributes to the activation of the NLRP3 inflammasomes [21,22,28]; therefore,
we hypothesized that Cbl may dampen NLRP3 inflammasome activation by targeting glycolysis.
We generated Cbl-KO THP-1 cells through clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 technology and characterized the expression of Cbl and NLRP3 inflammasome
components (Figure 1A). Consistent with our previous study, decreasing Cbl expression did not affect
the expression levels of NLRP3 inflammasomes [24]. To determine whether glycolysis is a Cbl target, we
measured the extracellular acidification rate (ECAR), an indicator of glycolysis, in Cbl-KO and wild-type
(WT) THP-1-derived macrophages. We found that Cbl-KO THP-1-derived macrophages had higher
rates of glycolysis than WT cells, as reflected by their maximal ECAR when elicited by the inhibition of
ATP synthase in OXPHOS with oligomycin, which revealed the glycolytic capacity (difference between
maximal ECAR and non-glycolytic acidification) and glycolytic reserve capacity (difference between
glycolytic capacity and basal glycolysis; Figure 1B). To examine whether an increase in glycolytic activity
due to Cbl deficiency was a general effect, we assessed glycolysis in Cbl-KO human embryo kidney
(HEK) 293T cells. Cbl-KO HEK293T cells with NLRP3 inflammasome reconstituted by transduction
were shown previously to have higher levels of NLRP3 inflammasome activation than in NLRP3
inflammasome-reconstituted WT HEK293T cells [24]. Thus, the loss of Cbl increased glycolytic capacity
and glycolytic reserve capacity in HEK293T cells (Figure 1C). Besides the increase in glycolytic activity
due to genetic loss of Cbl, we examined whether glycolysis was affected by pharmacological inhibition
with a Cbl-specific inhibitor, hydrocotarnine (CRIN-2, patent number: WO2011160016A2), which was
shown previously to interfere with the suppression effect of Cbl on NLRP3 inflammasome-dependent
IL-1β secretion [24]. As illustrated in Figure 1D, treatment with hydrocotarnine significantly increased
the glycolytic capacity and glycolytic reserve capacity in THP-1-derived macrophages, compared with
untreated control cells. Since glycolysis is a key metabolic pathway that feeds into mitochondrial
OXPHOS, we hypothesized that an increase of glycolytic capacity due to Cbl inhibition may enhance
the maximal rate of mitochondrial OXPHOS. As expected, Cbl-KO THP-1-derived macrophages
(Figure 1E) or Cbl-KO HEK293T cells (Figure 1F) had higher OXPHOS than WT cells, as reflected
by their maximal uncontrolled oxygen consumption rate (OCR), when elicited by the dissipation
of the mitochondrial electrochemical proton gradient with the mitochondrial uncoupler carbonyl
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), which revealed the maximum respiration
(difference between maximal OCR and non-mitochondrial respiration) and spare respiratory capacity
(SRC; difference between maximum respiratory capacity and basal respiratory capacity). Consistent
with the genetic depletion of Cbl, Cbl inhibition with hydrocotarnine increased the maximum respiration
and SRC of THP-1-derived macrophages (Figure 1G). Together, these data revealed that Cbl inhibition
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2.4. Inhibition
of Cbl Increased Cellular Glucose Uptake

Because glycolysis is regulated by Cbl and is critical for NLRP3 inflammasome activation (Figure 2),
we examined the mechanisms involved in Cbl-mediated glycolysis regulation. In a previous report,
Cbl-deficient mice displayed a marked improvement in glucose tolerance [27], suggesting that Cbl
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Figure 6. GLUT1 promoted cellular glucose uptake and NLRP3 inflammasome activation. (A)
Figure 6. GLUT1 promoted cellular glucose uptake and NLRP3 inflammasome activation. (A)
Immunoblot of GLUT1 in THP-1-derived macrophages treated with GLUT1 small interfering RNA
Immunoblot of GLUT1 in THP-1-derived macrophages treated with GLUT1 small interfering RNA
(siRNA) or control siRNA. (B) Flow cytometry plots of three experiments showing glucose uptake in
(siRNA) or control siRNA. (B) Flow cytometry plots of three experiments showing glucose uptake
WT and Cbl-KO THP-1-derived macrophages treated with GLUT1 siRNA or control siRNA. (C)
in WT and Cbl-KO THP-1-derived macrophages treated with GLUT1 siRNA or control siRNA. (C)
Immunoblot analysis of caspase-1 (p20) and IL-1β (p17) in culture supernatants of WT and Cbl-KO
Immunoblot analysis of caspase-1 (p20) and IL-1β (p17) in culture supernatants of WT and Cbl-KO
THP-1-derived macrophages treated with GLUT1 siRNA or control siRNA and then treated with
THP-1-derived
macrophages treated with GLUT1 siRNA or control siRNA and then treated with
nigericin. (D) Enzyme-linked immunosorbent assay of IL-1β in the supernatants of WT and Cbl-KO
nigericin.
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Together,
these novel
resultsinflammasome.
revealed a new mechanistic role for the
Cbl–GLUT1 axis in negative regulation of NLRP3 inflammasome.
Previously, we revealed that Cbl is crucial in suppressing NLRP3 inflammasome activation from
stimulation by nigericin or ATP [24]. The phosphorylation of Cbl is regulated by Src-family kinases,
and phosphorylation of Cbl at Tyr371 suppresses NLRP3 inflammasome activation [24]. Mechanistically,
Cbl reduces the level of phosphorylated Pyk2 (p-Pyk2) through post-transcriptional regulation and
ubiquitination-mediated proteasomal degradation. P-Pyk2 is required to directly phosphorylate the
caspase-recruitment domain of ASC at Tyr146, which converts ASC into an oligomerization-competent
state [25]. Upon NLRP3 stimulation, NLRP3 oligomers recruit ASC molecules and trigger ASC
oligomerization, which is essential for activating NLRP3 inflammasomes [25]. The lower level of
p-Pyk2 is regulated by Cbl, which thus dampens NLRP3 inflammasome activation. In addition to
the Cbl-p-Pyk2 pathway, we identified a new mechanism underlying Cbl-regulated inhibition of
NLRP3 inflammasomes. The low level of GLUT1 expression, which is regulated by Cbl through
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post-transcriptional regulation (Figure 5), inhibits glucose uptake and glycolytic metabolism and
finally dampens NLRP3 inflammasome activation and IL-1β secretion (Figure 6). Consistent with our
results, overexpression of GLUT1 in macrophages resulted in increased glucose uptake, increased
glucose utilization, and increased IL-1β expression [29,30], which suggested that GLUT1 is involved in
regulating IL-1β expression. In addition to the regulation of IL-1β expression, we noted that GLUT1
is involved in regulating IL-1β secretion by enhancing NLRP3 inflammasome activation. Together,
our studies have indicated that Cbl is a master regulator of NLRP3 inflammasomes. Cbl can inhibit the
NLRP3 inflammasomes through two pathways, by inhibition of p-Pyk2-regulated ASC oligomerization
and
of21,
GLUT1-regulated
glucose utilization.
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Figure 7.
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Several lines of evidence support the notion that energy metabolic remodeling, including
Previously, we revealed that Cbl is crucial in suppressing NLRP3 inflammasome activation from
glycolysis [21,22] and fatty acid oxidation [31,32], plays a role in NLRP3 inflammation activation.
stimulation by nigericin or ATP [24]. The phosphorylation of Cbl is regulated by Src-family kinases,
In response to various NLRP3 stimuli, metabolic remodeling activates NLRP3 inflammasomes through
and phosphorylation of Cbl at Tyr371 suppresses NLRP3 inflammasome activation [24].
ROS
production.Cbl
Although
is involved
in many physiological
functions,
it post-transcriptional
also causes cellular
Mechanistically,
reducesROS
the level
of phosphorylated
Pyk2 (p-Pyk2)
through
oxidative
damage
and
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been
linked
to
multiple
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including
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regulation and ubiquitination-mediated proteasomal degradation. P-Pyk2 is required to diseases,
directly
diabetes,
cancer,
and
premature
aging
[33].
Here,
we
noted
that
Cbl
is
involved
in
regulation
of
phosphorylate the caspase-recruitment domain of ASC at Tyr146, which converts ASC into an

oligomerization-competent state [25]. Upon NLRP3 stimulation, NLRP3 oligomers recruit ASC
molecules and trigger ASC oligomerization, which is essential for activating NLRP3 inflammasomes
[25]. The lower level of p-Pyk2 is regulated by Cbl, which thus dampens NLRP3 inflammasome
activation. In addition to the Cbl-p-Pyk2 pathway, we identified a new mechanism underlying Cblregulated inhibition of NLRP3 inflammasomes. The low level of GLUT1 expression, which is
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ROS production (Figure 3). Through GLUT1 inhibition, Cbl restrains the activation of glycolysis
and mitochondrial OXPHOS, which are required for ROS production and NLRP3 inflammasome
activation [21]. Even though Cbl dampens NLRP3 inflammasome activation, reduction of ROS
production by Cbl may limit ROS damage to the cells and thus help to maintain the health of cells.
Therefore, our results suggested a new role for Cbl in energy remodeling and energy homeostasis
through the regulation of glucose utilization. In agreement with our suggestion, Cbl-KO mice exhibited
higher energy expenditure and were protected from obesity, insulin resistance, and diabetes [27]. Our
new findings revealed a new role for Cbl in regulation of glucose utilization.
Diabetes is a metabolic disease in which glucose levels are too high in the blood vessels but are not
internalized and utilized by the cell. Our results showed that cellular glucose uptake was restrained
by Cbl (Figure 4) through GLUT1 inhibition (Figure 6B), which indicated that Cbl plays a role in
the regulation of glucose utilization, which may help to explain the diabetes resistance of Cbl-KO
mice [27]. Diabetes is also considered as an immune dysfunction disease, and patients with diabetes
have infections more often than people without diabetes [34,35]. Diabetes approximately doubles
the risk of cellulitis, compared with people without diabetes [34,36]. Common organisms that cause
cellulitis are Streptococcus pyogenes and Staphylococcus aureus [37,38]. The NLRP3 inflammasomes are
required for protecting mice from S. pyogenes or S. aureus infections [39,40]. Our results indicated that
Cbl inhibition with hydrocotarnine not only increases expression of GLUT1 (Figure 5) but also increases
cellular glucose uptake (Figure 4), which enhances NLRP3 inflammasome activation (Figures 2 and 6).
Therefore, we purpose that inhibition of Cbl with hydrocotarnine may protect people from diabetes
and contribute to the elimination of bacterial infections in diabetic people. Importantly, inhibition of
Cbl with hydrocotarnine increases inflammasome-mediated IL-18 secretion in the colon and protects
mice from dextran sulphate sodium-induced colitis [24]. Our present study provided new evidence to
support a novel clinical use for hydrocotarnine in disease treatment.
4. Materials and Methods
4.1. Cell Culture
The THP-1 (human leukemia monocytic) cell line was purchased from the Biosource Collection
and Research Center (Hsinchu, Taiwan) and maintained in Roswell Park Memorial Institute (RPMI)
medium, as described previously [41]. To generate Cbl-KO THP-1 cells, we manipulated THP-1 cells
with a lentiviral-based CRISPR/Cas9 system with small guide RNA (sgRNA) to target Cbl (GTCCA
CCGTC CCCGG CGGGT), followed by selection with puromycin, as described previously [24].
For Cbl inhibition, THP-1 cells were maintained in RPMI containing 50 µM hydrocotarnine (enamine).
For macrophage differentiation, THP-1 cells were stimulated with 200 nM phorbol 12-myristate
13-acetate for 16 h. The HEK293T cell line was obtained from American Type Culture Collection
(Rockville, MD, USA) and was grown in Dulbecco’s modified Eagle’s medium supplemented with 10%
(v/v) fetal bovine serum, penicillin (1000 U/mL), and streptomycin (50 µg/mL) with 5% CO2 at 37 ◦ C.
Cbl-KO HEK293T cells were generated as described previously [24]. For inflammasome stimulation,
the cells were treated with 10 µM nigericin for 45 min. For inhibition, 100 mM of 2DG (Sigma) and
NAC (25 mM) [13] were applied for 1 h and 5 min prior to inflammasome stimulation, respectively.
4.2. Seahorse Analysis
The Seahorse XF24 bioanalyzer (Seahorse Bioscience, Billerica, MA, USA) was used to
continuously monitor the ECAR and OCR. We plated 5 × 104 cells per well (THP-1 or Cbl-KO
THP-1 cells) or 4 × 104 cells per well (HEK293T or Cbl-KO HEK293T) on XF24 cell culture microplates
(Seahorse Bioscience). ECAR or OCR, as parameters of glycolytic flux and mitochondrial respiration,
were measured on a Seahorse XF24 bioanalyzer by using the Glycolysis Stress Test kit or Mito Stress
Test Kit (Seahorse Bioscience) according to the manufacturer’s instructions. To induce maximum OCR,
we used 1 and 0.3 µM of FCCP in THP-1 or Cbl-KO THP-1 cells and HEK293T or Cbl-KO HEK293T
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cells, respectively. Glycolytic capacity was calculated as the difference between maximum ECAR
measurement after oligomycin addition and the last ECAR measurement before glucose addition.
Glycolytic reserve capacity was calculated as the difference between the latest ECAR measurement
before and maximum ECAR measurement after oligomycin addition. Maximum respiration was
calculated as the difference between maximum OCR measurement after FCCP addition and minimum
OCR measurement after rotenone and antimycin A addition. SRC was calculated as the difference
between basal OCR and maximal OCR after the addition of FCCP.
4.3. Immunoblot Analysis
The procedure of immunoblot analysis was previously described [42]. To measure caspase-1
activation and IL-1β secretion, we concentrated culture supernatants using trichloroacetic acid protein
precipitation, followed by SDS-PAGE separation. The following primary antibodies were used for
the immunoblot: anti-ASC (1:1000; cat# SC-22514-R; Santa Cruz Biotechnology, Dallas, TX, USA),
anti-caspase-1 (1:300; cat# SC-56036; Santa Cruz Biotechnology), anti-IL-1β (1:1000; SC-32294; Santa
Cruz Biotechnology), anti-glyceraldegyde 3-phosphate dehydrogenase (GAPDH; 1:2000; SC-32233;
Santa Cruz Biotechnology), anti-NLRP3 (1:500; cat# AG-20B-0014; Adipogen, San Diego, CA,
USA), and anti-GLUT1 (1:1000; cat# ab115730; Abcam, Cambridge, United Kingdom). Secondary
antibodies used for immunoblotting were as follows: goat anti-rabbit immunoglobulin horseradish
peroxidase (IgG-HRP; 1:5000; cat# SC-2004; Santa Cruz Biotechnology) and sheep antimouse IgG-HRP
(1:5000; cat# NA931; Amersham, Amersham, United Kingdom). The immunoreactive protein bands
were visualized using the enhanced chemiluminescence system (cat# TU-ECL03; Biotools, Taiwan)
according to the manufacturer’s instructions.
4.4. Glucose Uptake Assay
THP-1-derived macrophages were incubated in RPMI medium with 10% fetal bovine serum
(FBS) and 5.5 mM glucose in the presence of 200 µM 2-NBDG for 16 h. The cellular glucose uptake
was determined by the fluorescence intensity of the internalized 2-NBDG that was measured using
flow cytometry.
4.5. Assessment of GLUT1 Expression by Flow Cytometry
For cell-surface GLUT1 detection, cells were stained with fluorescein isothiocynate-conjugated
anti-GLUT1 Ab (cat# FAB1418F; R&D systems, Minneapolis, MN, USA) at 4 ◦ C. Mouse IgG2b was
used as an isotype control. For total GLUT1 detection, cells were fixed and permeabilized at 4 ◦ C with
Intracellular Fixation and Permeabilization Buffer Set (cat# 88-8824; eBioscience, San Diego, CA, USA),
followed by GLUT1 staining. GLUT1 staining was measured using the FACSCalibur flow cytometer
and CellQuest pro software (BD Biosciences, San Jose, CA, USA).
4.6. Quantitative RT-PCR
RNA samples were isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA),
followed by reverse transcription of RNA (1 µg) using oligo(dT)20 primers (Invitrogen) and
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT; Invitrogen) according to the
manufacturer’s instructions. The following primers were used: GLUT1—forward 50 -CTTCT CCAAC
TGGAC CTCAA ATTT-30 and reverse 50 -CGGCC TTTAG TCTCA GGAAC TTT-30 , and GAPDH
(normalization control)—forward 50 -TGGTA TCGTG GAAGG ACTCA TGAC-30 and reverse 50 -ATGCC
AGTGA GCTTC CCGTT CAGC-30 . Quantitative RT-PCR was performed using a Light-Cycler
Instrument (Roche Diagnostics, Basel, Switzerland) with the FastStart DNA Master SYBR Green I
reagent (Roche Diagnostics).
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4.7. RNA Interference
The double-stranded RNA duplexes targeting GLUT1 were purchased from Dharmacon, and
the negative control siRNA was synthesized by Research Biolabs Ayer Rajah Industrial Estate
(Research Biolabs, Singapore). They were transfected into cells using Lipofectamine 2000, as previously
described [24]. For efficient knockdown, the cells were incubated for 2 days. The target sequence of
GLUT1 siRNA was 50 -AGACA UGGGU CCACC GCUA-30 .
4.8. IL-1β Enzyme-Linked Immunosorbent Assay
Cell culture supernatants were assayed for human IL-1β (eBioscience) as described previously [43].
4.9. Cellular ROS Production Assay
Cellular ROS was measured using 20 ,70 -dichlorodihydrofluorescein diacetate (H2 -DCFDA; Life
Technologies, Carlsbad, CA, USA) as described previously [24]. The cells were simultaneously treated
with 10 µM nigericin and 0.3 µM H2 -DCFDA for 30 min and then analyzed using flow cytometry.
4.10. Statistical Analysis
Statistical analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Differences
were considered significant at p < 0.05. The error bars were calculated and represented in terms of
mean ± SD.
5. Conclusions
In summary, we proposed a model for the previously unrecognized Cbl-GLUT1 axis-dependent
suppression of NLRP3 inflammasome activation. We discovered that Cbl inhibited surface expression
of GLUT1 protein, which in turn increased the threshold for NLRP3 inflammasome activation by
maintaining glycolysis, OXPHOS, and ROS at low levels. Our findings suggested that Cbl should be
considered a new therapeutic target of hydrocotarnine when treating inflammation-related diseases
related to NLRP3 inflammasome activation.
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